Publication date: Available online 12 November 2026 Source: Pharmacological Reviews Author(s): Fernando S. Carneiro, Fernanda R.C. Giachini, Morgan P. Fonseca, Andrey A. Porto, Jeimison D. Santos, Rita C. Tostes
The Pharmacology of Gender-Affirming Hormone Therapy: From Molecular Mechanisms to Clinical Physiologic and Pathophysiologic Implications. // Pharmacological Reviews. – URL: https://www.sciencedirect.com/science/article/pii/S003169972600061X?dgcid=rss_sd_all
The Pharmacology of Gender-Affirming Hormone Therapy: From Molecular Mechanisms to Clinical Physiologic and Pathophysiologic Implications. Pharmacological Reviews. https://www.sciencedirect.com/science/article/pii/S003169972600061X?dgcid=rss_sd_all
“The Pharmacology of Gender-Affirming Hormone Therapy: From Molecular Mechanisms to Clinical Physiologic and Pathophysiologic Implications.” Pharmacological Reviews.
@article{article31650,
title = {The Pharmacology of Gender-Affirming Hormone Therapy: From Molecular Mechanisms to Clinical Physiologic and Pathophysiologic Implications},
journal = {Pharmacological Reviews},
url = {https://www.sciencedirect.com/science/article/pii/S003169972600061X?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...